⌕
Alexion Pharmaceuticals · ALXN · Nasdaq
$182.50at last closeTenet 64 · Solid
Compare
$182.50at last closeTenet 64 · Solid

Alexion Pharmaceuticals (ALXN) Earnings Forecast

What Wall Street expects this business to earn, and how much analysts disagree.

Sources Analyst estimates EstimatesConsensus as of How we compute thisNot investment advice

Are estimates going up or down lately?

Our record of this company's consensus starts with tonight's snapshot. A revision needs two of our own nightly snapshots of one fiscal period to compare, and nothing before the first is reconstructed, because a backfilled revision is a number we never observed.

Measured between two of our own nightly snapshots of one fiscal period, so a new fiscal year entering the view is never read as a revision. Never backfilled. A window still filling says how many days it holds; a blank one means our record is not that long yet.

We hold no forward multiple for Alexion Pharmaceuticals today, so there is nothing here to set against the growth the Street expects.Show the multiple against its own recordHide the multiple record
Trailing P/E at each fiscal year end, FY08 to FY20 · over 11 fiscal years, with 2 years of near-zero earnings left out. The mark is the median of the last 10.
10.1× low104.9× high
65.1× median
We hold no trailing multiple for this company today, so nothing marks today on the track.

Does Alexion Pharmaceuticals usually beat or miss?

No quarter of Alexion Pharmaceuticals can be checked against an estimate, because no one publishes a quarterly estimate on it.

No quarter can be checked without a quarterly estimate. The record starts the night one is published and grows by one quarter every report after that.

Checked against the company's reported figure (GAAP) and the average estimate we recorded the night before its results release. Where analysts' number is on an adjusted basis, we leave the comparison out rather than force it.

These are consensus estimates: what analysts expect the business to earn, not where they think the stock trades. Coverage thins and the low to high band widens in the out-years. Context, not advice.

Analysts' price forecasts and grades are not licensed here. This page shows forward consensus estimates only: no near-year analyst count published. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.